accountmany conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and various fibrotic diseases. Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Amira Pharmaceuticals Announces Completion Of Phase 1 Clinical Study For AM152, A Novel LPA1 Receptor Antagonist
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account